Through development and commercialization partnerships, Sosei Heptares has already delivered two products to treat chronic obstructive pulmonary disease (COPD) and a treatment for orapharyngeal candidiasis. The legacy Novartis franchise continues to generate significant and stable revenue streams that enable further growth of the business.